Quintiles News Feed

QUINTILES NAMED ASIA-PACIFIC CONTRACT RESEARCH ORGANIZATION OF THE YEAR BY FROST & SULLIVAN

Fri, 09 Jul 2010 00:00:00 -0400

July 9, 2010 - Quintiles, has been named the 2010 Asia Pacific Contract Research Organization (CRO) Company of the Year by Frost & Sullivan.

QUINTILES ANNOUNCES CLINICAL RESEARCH PARTNERSHIP WITH THE UNIVERSITY MALAYA MEDICAL CENTRE

Mon, 05 Jul 2010 06:00:00 -0400

July 5, 2010 - Quintiles announces a strategic alliance agreement with the University Malaya Medical Centre (UMMC) as part of its unique Prime Site program - an initiative focused on accelerating the development of new and more effective medicines.

THE NEW HEALTH REPORT REVEALS PERCEPTION GAPS AMONG BIOPHARMA STAKEHOLDERS

Tue, 15 Jun 2010 09:00:00 -0400

June 15, 2010 - Newly published report details the differences between bio pharma and other key stakeholders as they grapple with industry challenges.

THE NEW HEALTH REPORT FINDS GREATER INFLUENCE FOR PATIENTS ON DRUG DEVELOPMENT

Tue, 15 Jun 2010 09:00:00 -0400

June 15, 2010 - Patients are emerging as an increasingly strong group when it comes to influencing the success and failure of new drugs – according to a newly published New Health Report commissioned by Quintiles.

QUINTILES ANNOUNCES SUITE OF PI3K BIOMARKER ASSAYS TO ADVANCE ONCOLOGY THERAPIES TARGETING THIS CANCER PATHWAY

Mon, 07 Jun 2010 09:00:00 -0400

June 7, 2010 - Suite is part of Quintiles Global Central Labs’ ongoing efforts to advance personalized medicine.

QUINTILES RATED NO. 1 PREFERRED PROVIDER & INDUSTRY LEADER ACROSS ALL PHASES OF CLINICAL RESEARCH

Tue, 01 Jun 2010 09:14:14 -0400

June 1, 2010 – Quintiles most consistently meets or exceeds customer expectations and is the No. 1 preferred provider and perceived industry leader across all phases of clinical research.

QUINTILES BOLSTERS MARKET ACCESS CAPABILITIES IN UK

Thu, 20 May 2010 07:43:12 -0400

May 20, 2010 – Quintiles today announced an agreement under which Nycomed has transferred a U.K.-based Healthcare Solutions Team to further strengthen Quintiles’ market access capabilities.

QUINTILES AND KAISER PERMANENTE ANNOUNCE ALLIANCE TO ACCELERATE DRUG DEVELOPMENT

Tue, 18 May 2010 00:00:00 -0400

May 18, 2010 - Quintiles is accelerating drug development with the addition of Kaiser Permanente's Southern California Permanente Medical Group to its global site program

QUINTILES GLOBAL CENTRAL LAB IN CHINA EARNS PRESTIGIOUS NATIONAL AWARD FROM LEADING MEDICAL CENTER

Tue, 30 Mar 2010 11:24:05 -0400

March 30, 2010 – Quintiles’ Global Central Laboratory in China has won the national “Best Central Lab 2009” award from Shanghai Mental Health Center.

QUINTILES EXAMINES ASIA-PACIFIC DRUG DEVELOPMENT LANDSCAPE IN NEW REPORT

Wed, 17 Mar 2010 06:00:00 -0400

March 17, 2010 - A new report from Quintiles analyzes the Asia-Pacific pharmaceutical development landscape and its evolution from outsourcing destination to potential innovation hub.

QUINTILES ANNOUNCES NEW CENTRAL LAB IN JAPAN

Mon, 15 Mar 2010 18:00:00 -0400

March 15, 2010 – Quintiles announces that it has successfully relocated its Global Central Laboratory in Japan from Saitama to Tokyo to allow for expansion.

QUINTILES EXPANDS TO EAST AFRICA

Thu, 11 Mar 2010 09:39:24 -0400

March 11, 2010 - Quintiles has expanded its capacity in Africa with the opening of an office in Nairobi, Kenya.

QUINTILES EXTENDS PHASE I CAPACITY AND CAPABILITIES

Mon, 08 Mar 2010 18:24:54 -0400

March 8, 2010 – Quintiles announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.

QUINTILES SPEEDS PATIENT RECRUITMENT WITH LOCAL MARKETING AUTOMATION TECHNOLOGY

Wed, 17 Feb 2010 11:12:46 -0400

Quintiles today launched innovative, web-based technology to enable world-class marketing for clinical trial enrollment at an individual site-level. Named Quintiles Trial Enrollment Accelerator (QTEA), this new solution will speed patient recruitment by helping customers better manage the quality, consistency and effectiveness of messaging and media outreach.

QUINTILES ADDS TISSUE TESTING SERVICES IN CHINA

Tue, 16 Feb 2010 09:43:33 -0400

February 16, 2010 - Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments.

Quintiles Again Named to Training Top 125, for Workforce Training and Development Excellence

Mon, 08 Feb 2010 08:39:29 -0400

Quintiles has again been named to Training magazine’s “Training Top 125,” the publication’s annual report that ranks companies based on their employer-sponsored training and development programs.

QUINTILES AND MOVETIS ANNOUNCE STRATEGIC ALLIANCE

Thu, 28 Jan 2010 10:32:01 -0400

January 28, 2010 - Quintiles announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany.

QUINTILES ANNOUNCES NEW POSITIONING, NEW BRAND IDENTITY

Mon, 25 Jan 2010 06:00:00 -0400

January 25, 2010 – Quintiles, the world’s leading biopharmaceutical services company, has launched a new positioning and brand identity, driven by the company’s growing ability to solve customers’ emerging clinical and commercial challenges.

QUINTILES EXECUTIVE ELECTED CHAIR-ELECT OF CDISC

Tue, 19 Jan 2010 09:30:17 -0400

January 19, 2010 – Quintiles announced that Paula Brown Stafford, Executive Vice President, Integrated Clinical Services, has been elected chair-elect of the Board of Directors of CDISC, a global organization that leads the development of standards to reduce complexity in biomedical research to speed new therapies to market and improve the flow of research information to healthcare.

QUINTILES SELECTS INVIVODATA AS PRIMARY PARTNER FOR ePRO SOLUTIONS

Mon, 18 Jan 2010 09:53:33 -0400

January 18, 2010 — Quintiles, the world’s leading biopharmaceutical services company, and invivodata, inc., an industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, announced a collaboration agreement to transform the way Patient Reported Outcomes (PRO) are used in clinical research to speed drug development.

QUINTILES’ SUCCESS IN MANAGING STRATEGIC ALLIANCES PROFILED IN HARVARD BUSINESS REVIEW

Mon, 11 Jan 2010 06:00:00 -0400

January 11, 2010 - “Managing Alliances with the Balanced Scorecard” details how Solvay Pharmaceuticals and Quintiles managed their innovative development alliance to deliver value for both companies. Article appeared in special double issue (January-February 2010) of Harvard Business Review.

QUINTILES VIRTUAL CLINICAL RESEARCH COMMUNITY REACHES 2 MILLION

Tue, 22 Dec 2009 16:51:14 -0400

December 22, 2009 – Quintiles announced it has developed a community of more than 2 million clinically profiled patients who have opted in to volunteer or provide insights and guidance to advance clinical research through its proprietary Web site iGuard.org.

QUINTILES HONORED AS CRO OF THE YEAR AT 2009 SCRIP AWARD

Mon, 14 Dec 2009 12:02:36 -0400

Research Triangle Park, NC, December 14, 2009 – Quintiles has been named CRO of the Year by the prestigious SCRIP Awards. The panel of judges highlighted Quintiles’ breadth of services and its outstanding relationships with clients.

QUINTILES OPENS EXPANDED ASIA-PACIFIC HEADQUARTERS IN SINGAPORE

Fri, 06 Nov 2009 10:47:04 -0400

November 6, 2009 - To meet the growing demand for its services throughout the Asia-Pacific region, Quintiles announced the official grand opening of its expanded Asia-Pacific regional headquarters facility in Singapore's Science Park I.

QUINTILES’ BILL DEAM NAMED TO CIO HALL OF FAME

Mon, 02 Nov 2009 15:42:10 -0400

November 2, 2009 - Quintiles Executive Vice President and Chief Information Officer (CIO) William “Bill” Deam has been named to the “CIO Hall of Fame” which selects honorees for their leadership in the CIO community and contributions to the advancement of the profession.

QUINTILES ANNOUNCES CLINICAL PHARMACOLOGY ALLIANCE WITH ASTRAZENECA

Mon, 02 Nov 2009 09:39:26 -0400

November 2, 2009 - Quintiles has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.

QUINTILES ANNOUNCES STRATEGIC ALLIANCE TO ADVANCE EISAI’S ONCOLOGY PIPELINE

Fri, 30 Oct 2009 08:07:38 -0400

October 30, 2009 - Quintiles announced a strategic alliance with leading global pharmaceutical company Eisai Co. Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai’s R&D pipeline.

QUINTILES CONSULTING STRENGTHENS REGULATORY & QUALITY CAPABILITIES

Thu, 29 Oct 2009 08:51:24 -0400

October 29, 2009 - Quintiles Consulting today announced three key appointments in its US Regulatory and Quality consulting practice. These new appointments expand Quintiles’ experience in regulatory compliance and quality system development.

QUINTILES PARTNERS WITH FOUNDATION TRUST & UNIVERSITY TO IMPROVE PATIENT CARE AND DRIVE EFFICIENCY IN CLINICAL RESEARCH

Mon, 26 Oct 2009 11:53:57 -0400

October 26, 2009 - A significant step in driving innovation, improving patient care and increasing efficiency in early stage clinical research was taken today with the announcement that two of the UK’s leading institutions - Guy’s and St Thomas’ NHS Foundation Trust and King’s College London - have signed a collaborative agreement with Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide.

QUINTILES CONSULTING EXPLORES IMPACT OF COMPARATIVE EFFECTIVENESS RESEARCH ON DRUG DEVELOPMENT

Wed, 21 Oct 2009 13:45:26 -0400

October 21, 2009 – In a new report released today, John Doyle, Vice President and Practice Leader for Quintiles Consulting, and an expert on pharmaceutical market access, explores the complex issue of comparative effectiveness research (CER) and its strategic importance in successful and efficient biopharmaceutical development.

QUINTILES AND CERNER WORK TOGETHER TO IMPROVE EFFICIENCY OF LATE PHASE RESEARCH STUDIES

Thu, 01 Oct 2009 16:21:56 -0400

October 1, 2009 – Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting

QUINTILES LAUNCHES CLINICALRESEARCH.COM

Wed, 30 Sep 2009 11:19:49 -0400

September 30, 2009 - Patients who want to play an active role in bringing new, safer drugs to market faster now have access to a global Web site that makes it easier than ever before to identify clinical trials to participate in – regardless of geography or the drug company sponsor.

INNOVEX AND HEALTHCARE AT HOME ANNOUNCE JOINT VENTURE

Tue, 29 Sep 2009 14:00:32 -0400

September 29, 2009 - Innovex, a Quintiles company, and Healthcare at Home today announced that they have agreed to form an innovative healthcare joint venture in Europe, named Healthcare at Home Europe.

QUINTILES AND ALLERGAN ANNOUNCE CO-PROMOTION AGREEMENT

Fri, 25 Sep 2009 09:54:10 -0400

September 25, 2009 – Quintiles Transnational Corp. and Allergan, Inc. today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR®.

QUINTILES INCREASES CAPACITY TO SUPPORT EUROPEAN CLINICAL TRIALS

Thu, 24 Sep 2009 11:39:33 -0400

September 24, 2009 - Quintiles Transnational Corp. today announced the opening of an expanded regional facility near Edinburgh, Scotland. Located within the Alba Campus, a research and development center near Edinburgh, the 115,000-square-foot building hosts more than 500 employees and has space for Quintiles Clinical Development Services, including Project Management, Regulatory Affairs and Data Management.

QUINTILES DEBUTS AT #50 IN INFORMATIONWEEK 500

Tue, 15 Sep 2009 15:20:41 -0400

September 15, 2009 - Quintiles has been ranked in the 2009 InformationWeek 500, the publication’s annual ranking of the nation’s most innovative users of information technology. Quintiles was ranked 50th in its first time on the list.

QUINTILES ADDS DIGITAL PATHOLOGY SERVICES

Mon, 14 Sep 2009 10:45:23 -0400

September 14, 2009 - Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to treat the world’s most pressing health issues, including cancer.

QUINTILES ANNOUNCES CLINICAL RESEARCH PARNERSHIP WITH THE UNIVERSITY OF PRETORIA

Thu, 10 Sep 2009 13:54:23 -0400

September 10, 2009 – Quintiles Prime Site Program expands into South Africa to accelerate clinical development.

QUINTILES ANNOUNCES NEW GHANA OFFICE

Tue, 16 Jun 2009 13:30:31 -0400

June 16, 2009 - To improve efficiency and expand capacity to monitor the growing number of clinical studies being conducted in Western Sub-Saharan Africa, Quintiles today announced the opening of a new office in Accra, Ghana.

QUINTILES AGAIN NAMED TO COMPUTERWORLD’s “100 BEST PLACES TO WORK IN IT” LIST

Mon, 15 Jun 2009 10:57:23 -0400

June 15, 2009 - Quintiles Transnational Corp. has been named to Computerworld magazine’s “100 Best Places to Work in IT” list for the second year in a row, improving to a ranking of 16th on the 2009 list.

QUINTILES CONSULTING OFFERS WHITE PAPER ON COST CONTAINMENT

Thu, 11 Jun 2009 10:49:05 -0400

June 11, 2009 - Quintiles Consulting today released the first in a three-part series of white papers addressing how best to navigate risk in drug development. The first paper, “On the Re-Balancing of Risk to Transform Cost and Productivity in Drug Development,” focuses on operational risk. It is available for download at http://www.quintiles.com/consulting/.

QUINTILES WINS PFIZER DEVELOPMENT OPERATIONS STRATEGIC SUPPLIER EXCELLENCE AWARD

Wed, 10 Jun 2009 13:47:36 -0400

JUNE 10, 2009 – Quintiles announces that its Data Management division has received the 2008 Pfizer Development Operations’ Strategic Supplier Excellence Award.

QUINTILES ADVANCES CANCER TREATMENT THROUGH NEW GENETIC TESTS

Mon, 25 May 2009 11:43:19 -0400

May 26, 2009 – Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announces the availability of two new laboratory tests used to develop more effective cancer treatments.

QUINTILES ANNOUNCES APPOINTMENT OF NEW PRACTICE LEADER

Mon, 27 Apr 2009 13:37:57 -0400

April 28, 2009 - Quintiles Consulting announced the appointment of James Kirk as Practice Leader for Eidetics, the Market Intelligence and Analytics Practice of Quintiles Consulting.

QUINTILES NAMED BEST CLINICAL SERVICE PROVIDER

Thu, 23 Apr 2009 11:12:39 -0400

April 23, 2009 - Quintiles was named by industry decision-makers as the most favored contract research organization (CRO), according to two recently released independent surveys.

QUINTILES CANADA RECOGNIZED AS A GREAT PLACE TO WORK

Wed, 15 Apr 2009 15:25:10 -0400

April 15, 2009 - Quintiles has been recognized by the Great Place to Work® (GPTW) Institute Canada as one of the top 25 companies to work for in the country.

QUINTILES APPOINTS RICHARD PILNIK TO HEAD INNOVEX

Tue, 07 Apr 2009 12:24:59 -0400

April 7, 2009 - Quintiles Transnational Corp. announced the appointment of Richard (Rich) Pilnik to serve as president of Innovex.

QUINTILES REACHES 400TH TRIAL USING ELECTRONIC DATA CAPTURE

Thu, 02 Apr 2009 14:57:40 -0400

April 2, 2009 – Quintiles Transnational Corp. announced the achievement of another industry-leading milestone – its 400th clinical trial using Electronic Data Capture (EDC).

QUINTILES GLOBAL CENTRAL LABORATORY NETWORK SETS NEW STANDARD

Wed, 11 Mar 2009 14:13:15 -0400

March 11, 2009 – Quintiles Transnational Corp. has the largest CAP-accredited central laboratory network in the world - setting a standard for patient safety and faster drug development.

QUINTILES CENTRAL LAB IN ARGENTINA RECEIVES CAP ACCREDIATION

Wed, 11 Mar 2009 09:14:44 -0400

March 11, 2009 - Quintiles Central Lab in Buenos Aires is latest facility to be accredited in the world’s largest CAP-accredited lab network.

QUINTILES AMONG BEST COMPANIES TO WORK FOR ACROSS EUROPE

Fri, 27 Feb 2009 14:16:59 -0400

BRACKNELL, UK. – February 27, 2009– Quintiles and Innovex have been recognized by the Great Places to Work® (GPTW) Institute in the top 100 “Best Companies to Work For” in Ireland, Germany and Italy.

QUINTILES NAMED TO TRAINING TOP 125 FOR WORKFORCE TRAINING AND DEVELOPMENT EXCELLENCE

Thu, 26 Feb 2009 13:37:15 -0400

February 26, 2009 – Quintiles Transnational Corp. has been named to TRAINING magazine’s “Training Top 125,” the publication’s annual report that ranks companies based on their employer-sponsored training and development programs.

QUINTILES TO OPEN PHASE I UNIT IN INDIA

Tue, 27 Jan 2009 11:14:10 -0400

January 27, 2009 – Quintiles Transnational Corp. announced a partnership with Apollo Hospitals Group to open a Phase I clinical trial unit in Hyderabad, India.

QUINTILES MOVES TO SPEED DEVELOPMENT OF CANCER THERAPIES

Thu, 15 Jan 2009 12:26:24 -0400

January 15, 2009 - Quintiles Transnational Corp. announced that it has adopted “common contract language” to significantly reduce contract negotiation time, and shorten the drug testing process.

QUINTILES ACQUIRES TARGETED MOLECULAR DIAGNOSTICS (TMD)

Mon, 01 Dec 2008 10:15:31 -0400

December 1, 2008 - Quintiles Transnational Corp. today announced that it has acquired Targeted Molecular Diagnostics (TMD) of Westmont, Ill.

QUINTILES, SAS ANNOUNCE DEVELOPMENT OF FIRST-EVER CLINICAL TRIALS STATISTICAL PROGRAMMING CERTIFICATION

Wed, 19 Nov 2008 14:36:21 -0400

November 19, 2008 - Quintiles, the world’s No. 1 pharmaceutical services company, and SAS are developing a unique program to produce certified specialists in the use of SAS programming to evaluate clinical trials results, the companies announced today.

EIDETICS LAUNCHES GROUNDBREAKING DATA VISUALIZATION

Fri, 24 Oct 2008 17:07:43 -0400

October 24, 2008 - Eidetics, a leading global healthcare market research firm and division of Quintiles Consulting, announced the commercial launch of their proprietary service application, Provenance.

QUINTILES RECOGNIZED AMONG "BEST COMPANIES TO WORK FOR" IN BRAZIL

Thu, 11 Sep 2008 17:41:27 -0400

September 11, 2008 -- Quintiles has been recognized by the Great Places to Work® (GPTW) Institute as one of the top 100 “Best Companies to Work For” in Brazil.

QUINTILES GDRU RECEIVES PHASE I SUPPLEMENTARY ACCREDITATION

Wed, 10 Sep 2008 14:51:11 -0400

September 10, 2008 - Quintiles Guy’s Drug Research Unit (GDRU) has been awarded supplementary accreditation for Phase I clinical trials, under a new approval programme that has been introduced by the Medicines and Healthcare Regulatory Agency (MHRA).

NOVAQUEST RECEIVES LILLY'S HIGHEST HONOR

Tue, 02 Sep 2008 12:24:27 -0400

September 2, 2008 - NovaQuest has received Eli Lilly and Company’s highest award for its “flawless execution” over four years in helping Lilly achieve strategic and operational objectives vital to its business success.

QUINTILES NAMED TO COMPUTERWORLD MAGAZINE’S ‘100 BEST PLACES TO WORK IN IT’

Mon, 14 Jul 2008 15:16:08 -0400

July 14, 2008 – Quintiles Transnational Corp. has been named to Computerworld magazine’s 2008 list of the "100 Best Places to Work in IT."

QUINTILES SIGNS AGREEMENT TO ACQUIRE EIDETICS

Wed, 07 May 2008 15:39:52 -0400

May 7, 2008 - Quintiles Transnational Corp. announced that it has signed an agreement to acquire Eidetics, a privately held decision-analytics and market research consulting firm located in Boston as part of its expanding Quintiles Consulting business.

QUINTILES CONSULTING BUSINESS EXPANDS; NEW PRACTICE LEADERS APPOINTED

Tue, 22 Apr 2008 15:56:13 -0400

April 22, 2008 – Quintiles Transnational Corp. announced the appointment of three new practice leaders and a business development head as part of its expanding Quintiles Consulting business.

QUINTILES APPOINTS OREN COHEN TO SENIOR VICE PRESIDENT, CLINICAL RESEARCH STRATEGIES

Wed, 16 Apr 2008 16:14:39 -0400

April 16, 2008 – Quintiles Transnational Corp. announced the appointment of Oren Cohen, M.D. as Senior Vice President, Clinical Research Strategies.

QUINTILES RANKS FIRST IN PAN-EUROPEAN CLINICAL INVESTIGATOR STUDY

Thu, 10 Apr 2008 16:18:35 -0400

April 10, 2008 – Quintiles Transnational Corp. announced that an independently conducted study of clinical investigator sites across Europe placed Quintiles first in overall satisfaction.

QUINTILES TO PROVIDE CENTRAL LAB SERVICES IN JAPAN

Wed, 26 Mar 2008 17:45:39 -0400

March 26, 2008 – Quintiles Transnational Corp. announced an agreement with Medca Japan to provide central laboratory services, further extending the Quintiles global network of laboratories certified by the College of American Pathologists (CAP).

QUINTILES DATA MANAGEMENT SURPASSES 300 EDC TRIALS

Wed, 05 Mar 2008 17:49:47 -0400

March 5, 2008 – Quintiles Transnational Corp. announced it has achieved another major milestone in the management of clinical trial data – 300 clinical trials using Electronic Data Capture (EDC).

QUINTILES CENTRAL LABORATORY IN INDIA RECEIVES CAP CERTIFICATION

Wed, 13 Feb 2008 16:34:40 -0400

February 13, 2008 – Quintiles Transnational Corp. announced that its central laboratory in India has been certified by the College of American Pathologists (CAP).

QUINTILES COMPLETES PREVIOUSLY ANNOUNCED NEW INVESTOR PARTNERSHIP, CO-LED BY FOUNDER, CHAIRMAN AND CEO DENNIS GILLINGS,

Thu, 24 Jan 2008 17:23:31 -0400

January 24, 2008 – Quintiles Transnational Corp. announced the completion of its previously announced new investor partnership to support the company’s continued growth under the leadership of founder and current Chairman and CEO Dennis Gillings, CBE, and the management team.

QUINTILES TO OPEN CLINICAL RESEARCH OFFICE IN WILMINGTON, NC

Thu, 17 Jan 2008 17:53:22 -0400

January 17, 2008 – Quintiles Transnational Corp. announced that the global leader in pharmaceutical services will open an office in Wilmington, N.C.

QUINTILES CENTRAL LAB, CLINICAL DEVELOPMENT IN CHINA TO EXPAND, RELOCATE TO NEW FACILITY

Wed, 09 Jan 2008 17:57:04 -0400

January 9, 2008 – Quintiles Transnational Corp. announced the expansion and consolidation of its Global Central Laboratories and Clinical Development Services (CDS) units in Beijing to accommodate their growing business in China.

QUINTILES NAMES KELLY MCKEE EXECUTIVE DIRECTOR OF OPERATIONS FOR PUBLIC HEALTH AND GOVERNMENT SERVICES UNIT

Wed, 09 Jan 2008 17:29:05 -0400

January 9, 2008 – Quintiles Transnational Corp. announced the appointment of Kelly McKee, M.D., as Executive Director of Operations for the company’s Public Health and Government Services unit.

QUINTILES NAMES HEAD OF STRATEGIC RESEARCH, MEDICAL, REGULATORY, AND SAFETY SERVICES

Tue, 08 Jan 2008 17:34:04 -0400

January 8, 2008 – Quintiles Transnational Corp. announced the appointment of Dipti Amin, M.D., as Senior Vice President of Strategic Research and Safety Services (SRS) and Medical and Regulatory Services, effective immediately.

QUINTILES TRANSNATIONAL FORMS NEW OWNERSHIP TEAM WITH CURRENT INVESTORS GILLINGS, TPG AND TEMASEK JOINED BY BAIN CAPITAL

Fri, 21 Dec 2007 15:52:38 -0400

December 21, 2007 – Quintiles Transnational Corp. today announced the formation of a new investor partnership to support the company’s continued growth under the leadership of current Chairman and CEO Dennis Gillings, CBE, and the management team. Gillings and global private investment firms Bain Capital and TPG Capital are the lead investors in the partnership, with 3i also becoming a significant investor. Temasek Holdings remains an investor in Quintiles.

QUINTILES APPOINTS JOHN GOODACRE AS GENERAL COUNSEL

Tue, 11 Dec 2007 16:19:27 -0400

December 11, 2007 – Quintiles Transnational Corp. today announced the appointment of John Goodacre as Executive Vice President and General Counsel.

FORCELOGIX, INNOVEX WIN SALES OPERATIONAL PERFORMANCE AWARD

Mon, 12 Nov 2007 16:28:26 -0400

Nov. 12, 2007 – ForceLogix and Innovex have received the Ventana Research 2007 Operational Performance Leadership Award for Sales, honoring the companies’ combined excellence in orchestrating people, process, information and technology for optimal sales business impact.

QUINTILES CONSULTING ENTERS RESEARCH PARTNERSHIP

Wed, 07 Nov 2007 10:11:26 -0400

November 7, 2007 – Quintiles Consulting, a leading provider of product development, regulatory and market strategies to the pharmaceutical, biotech and medical device industries, today announced a new research partnership with the Institute for Life Sciences Business Economics (iLSBE) at the Erasmus University of Rotterdam.

QUINTILES ACQUIRES CENTRAL AMERICAN RESEARCH ORGANIZATION

Tue, 30 Oct 2007 13:21:27 -0400

October 30, 2007 – Quintiles Transnational Corp. today announced that its Latin American subsidiary has purchased Bio-Trials, a leading Central American Clinical Research Organization (CRO) with headquarters in Panama and offices in Costa Rica, Guatemala, Ecuador and Peru.

EXPERT CARDIOLOGIST JOINS QUINTILES MEDICAL GROUP

Fri, 26 Oct 2007 13:48:09 -0400

October 26, 2007 – Quintiles Transnational Corp. today announced that Christopher H. Cabell, M.D., MHS, FACC, an expert cardiologist and clinical investigator, has joined the Medical & Scientific Services group in Global Clinical Development Services (CDS). In addition to his CDS work, he provides U.S.-based cardiology expertise for Quintiles ECG Services.

QUINTILES APPOINTS JAY D. NORMAN TO EXPAND CONSULTING BUSINESS

Mon, 08 Oct 2007 14:10:17 -0400

October 8, 2007 – Quintiles Transnational Corp. today announced the appointment of Jay D. Norman to serve as President of its expanding Quintiles Consulting business, which helps pharmaceutical, biotech and medical device companies maximize potential and minimize risk from early discovery through commercialization.

MICHAEL TROULLIS APPOINTED CHIEF FINANCIAL OFFICER OF QUINTILES TRANSNATIONAL CORP.

Wed, 15 Aug 2007 14:32:41 -0400

August 15, 2007 – Quintiles Transnational Corp. today announced the appointment of Michael Troullis as its Chief Financial Officer, effective immediately. Troullis had been acting CFO since former CFO John Ratliff was appointed Quintiles’ Chief Operating Officer last year.

QUINTILES TO ADD JOBS, CONSOLIDATE ATLANTA FACILITIES

Thu, 05 Jul 2007 08:33:28 -0400

July 5, 2007 – Quintiles Transnational Corp. today announced plans to expand and consolidate its Global Central Laboratories in Smyrna, Ga., and its Clinical Development Services (CDS) office in Atlanta within a single structure in nearby Marietta, Ga.

INVESTIGATORS REPORT STRONGER RELATIONSHIPS WITH QUINTILES THAN ANY OTHER CRO

Thu, 21 Jun 2007 14:36:40 -0400

June 21, 2007 – Quintiles Transnational Corp. today announced that clinical investigators rate their relationships with Quintiles the best in the industry, according to a recent survey.

QUINTILES ASIA PACIFIC WINS THREE AWARDS FOR EXCELLENCE

Mon, 11 Jun 2007 14:56:40 -0400

RESEARCH TRIANGLE PARK, N.C. – June 11, 2007 – Quintiles Transnational Corp. today announced that its Asia Pacific unit has received three awards for excellence in customer service.

QUINTILES CLINICAL TRIAL MONITORS RATED BEST IN INDUSTRY

Mon, 11 Jun 2007 14:51:26 -0400

June 11, 2007 – Quintiles Transnational Corp. today announced that clinical investigators rate Quintiles’ clinical trial monitors as the best in the industry, according to a recent survey.

QUINTILES TO BUILD NEW STRUCTURE FOR EXPANSION IN SCOTLAND

Wed, 06 Jun 2007 08:46:42 -0400

June 6, 2007 – Quintiles Transnational Corp. today announced that it plans to build a new office near Edinburgh that will be the Scotland home for its Product Development business, including Quintiles Laboratories, and its NovaQuest group. The company also will add 150 jobs in Scotland over the next four years.

QUINTILES AND THERMO FISHER SCIENTIFIC CREATE JOINT VENTURE TO PROVIDE INTEGRATED RESPONSE TECHNOLOGY SERVICES

Mon, 21 May 2007 15:11:04 -0400

May 21, 2007 – Quintiles Transnational Corp. and Thermo Fisher Scientific Inc. (NYSE: TMO) today announced the creation of a joint venture, called Cenduit™, that provides seamless, integrated Interactive Response Technology (IRT) services for pharmaceutical and biotechnology product development.

QUINTILES FOUNDER DEDICATES NEW FACILITY FOR CLINICAL RESEARCH IN OVERLAND PARK, KANSAS

Tue, 15 May 2007 15:15:56 -0400

May 15, 2007 – Dennis Gillings, CBE, Chairman and CEO of Quintiles Transnational Corp., today dedicated a new Quintiles facility in Overland Park, Kan., with Secretary David Kerr of the Kansas Department of Commerce and other dignitaries attending.

NEW REGULATORY TEAM AT QUINTILES HELPS BRING BIOTECHNOLOGY PRODUCTS TO MARKET

Mon, 07 May 2007 15:25:51 -0400

May 7, 2007 – Quintiles Transnational Corp. today announced the formation of a global biologics regulatory team to advise customers about development plans and optimal strategy for regulatory submissions for vaccines, monoclonal antibodies, stem-cell based therapies and other biological products.

QUINTILES CELEBRATES 10 YEARS IN INDIA WITH DEDICATION OF NEW LAB

Fri, 06 Apr 2007 08:57:19 -0400

April 6, 2007 – Dennis Gillings, CBE, Chairman and CEO of Quintiles Transnational Corp., today dedicated the company’s new central lab in Mumbai, India, and congratulated Quintiles India for its 10 years of growth and leadership in clinical research.

COMMERCE SECRETARY FAIN JOINS QUINTILES IN DEDICATING NEW DATA PROCESSING CENTER IN EASTERN NORTH CAROLINA

Tue, 13 Feb 2007 09:02:40 -0400

Feb. 13, 2007 – Dennis Gillings, CBE, Chairman and CEO of Quintiles Transnational Corp., was joined yesterday in the formal opening of Quintiles’ new data processing facility in Williamston, N.C., by North Carolina Commerce Department Secretary Jim Fain, together with N.C. Rep. Edith Warren; Tommy Bowen, Chairman of the Martin County Board of Commissioners; Stan Crowe, Chairman of the Martin County Economic Development Commission; and Jane Patterson, Executive Director of the e-NC Authority, a division of the North Carolina Rural Economic Development Center.

QUINTILES DATA MANAGEMENT HEAD ELECTED TO CDISC BOARD

Mon, 06 Nov 2006 09:12:52 -0400

November 6, 2006 – Quintiles Transnational Corp. today announced that Paula Brown Stafford, Executive Vice President, Global Data Management, has been elected to the Board of Directors of CDISC, an industry consortium that leads the development of data standards to improve medical research.

SOLVAY, QUINTILES ANNOUNCE FIVE-YEAR RENEWAL OF DRUG DEVELOPMENT STRATEGIC ALLIANCE

Tue, 24 Oct 2006 09:21:13 -0400

October 24, 2006 – Solvay Pharmaceuticals has renewed for another five years its clinical development strategic alliance with Quintiles, first signed in 2001, Solvay Pharmaceuticals and Quintiles Transnational Corp. announced today. The renewal reflects the alliance's success in accelerating development of Solvay's product portfolio and improving efficiency.

QUINTILES TO OPEN CENTRAL LABORATORY IN MUMBAI, INDIA

Mon, 16 Oct 2006 09:38:45 -0400

October 16, 2006 – Quintiles Transnational Corp. today announced plans to open a central lab in Mumbai, India, further expanding the company’s global network of labs that support global and regional clinical trials.

JOHN RATLIFF APPOINTED CHIEF OPERATING OFFICER OF QUINTILES TRANSNATIONAL CORP.

Mon, 02 Oct 2006 09:42:48 -0400

October 2, 2006 – Quintiles Transnational Corp. today announced that John Ratliff has been appointed as its new Chief Operating Officer, effective immediately. He will be responsible for directing Quintiles’ daily global operations and will report to Chairman and Chief Executive Officer, Dennis Gillings, CBE. Ratliff also has been elected to the Quintiles Transnational Corp. Board of Directors.

QUINTILES TO OPEN DATA PROCESSING CENTER IN MARTIN COUNTY, N.C.

Tue, 08 Aug 2006 09:50:04 -0400

August 8, 2006 – Quintiles Transnational Corp. today announced the expansion of its global data management network with the opening of a clinical data processing center in Williamston, N.C. The center will provide up to 70 new jobs in the eastern region of the state and build additional capacity for customers seeking services provided by U.S.-based staff.

HIGH-RANKING FDA OFFICIAL STEVEN NIEDELMAN JOINS QUINTILES CONSULTING AS EXECUTIVE VICE PRESIDENT

Tue, 01 Aug 2006 09:54:10 -0400

August 1, 2006 – Steven M. Niedelman, formerly deputy associate commissioner for Regulatory Operations for the U.S. Food and Drug Administration, has joined Quintiles Consulting as executive vice president, Quintiles Transnational Corp. announced today.

QUINTILES CREATES BIOSTATISTICS UNIT TO REDUCE TIME AND COSTS OF DRUG DEVELOPMENT

Mon, 24 Jul 2006 09:58:16 -0400

July 24, 2006 – Quintiles Transnational Corp. today announced the creation of the Strategic Biostatistics Unit to help customers cut the time and reduce the costs of drug development through the "adaptive design" of clinical trials and other innovative statistical approaches.

QUINTILES ASIA PACIFIC RECEIVES FROST & SULLIVAN AWARDS

Tue, 06 Jun 2006 10:01:29 -0400

June 6, 2006 – Quintiles Transnational Corp. today announced that its Quintiles East Asia subsidiary has been named the Asia Pacific region's Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year by the consulting firm Frost & Sullivan.

QUINTILES LAUNCHES NOVAQUEST AND ANNOUNCES ALLIANCE

Thu, 11 May 2006 10:09:56 -0400

May 11, 2006 – Quintiles Transnational Corp. today announced the launch of its expanded strategic partnering group under the NovaQuest™ brand and, to further NovaQuest's mission, an alliance with TPG-Axon Capital, a global investment firm with over $5.8 billion in equity capital. NovaQuest helps life-science companies realize greater value from their product portfolios through innovative strategic partnering solutions.

QUINTILES COMPLETES REFINANCING AND ACCEPTS NOTES IN TENDER OFFER

Fri, 31 Mar 2006 10:11:50 -0400

March 31, 2006 – Quintiles Transnational Corp. today announced that it has completed new credit facility arrangements. The new credit facilities include a $225 million first lien revolving credit facility due in 2012, a $1.0 billion first lien term loan due in 2013 and a $220 million second lien term loan due in 2014. Proceeds from the borrowings under the term loans were used, together with available cash, to pay the purchase price for notes accepted in the tender offer described below and to cash out the outstanding preferred stock of Pharma Services Holding, Inc. ("Pharma Services"), the parent company of Quintiles, as part of the mergers of Pharma Services and Pharma Services Intermediate Holding Corp. ("Holding") into Quintiles.

YOH NARIMATSU APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER OF QUINTILES JAPAN

Wed, 29 Mar 2006 10:14:51 -0400

March 29, 2006 – Quintiles Transnational Corp. today announced the appointment of Yoh Narimatsu as President and Chief Executive Officer of Quintiles Transnational Japan K.K. (Quintiles Japan) effective April 1.

QUINTILES TRANSNATIONAL CORP. ANNOUNCES DONATION TO SEATTLE VACCINE RESEARCH FUND

Tue, 21 Mar 2006 10:21:01 -0400

March 21, 2006 – Quintiles Transnational Corp., the world's leading pharmaceutical services organization, today announced it has donated $100,000 to the Seattle Vaccine Research Fund (SVRF) to support anti- retroviral treatment for HIV vaccine trial participants who become infected during vaccine studies.

QUINTILES DATA MANAGEMENT TO CONDUCT 200TH EDC TRIAL

Mon, 20 Mar 2006 10:43:33 -0400

March 20, 2006 – Quintiles Transnational Corp. today announced that it has reached a significant milestone in data management – the 200th clinical trial using Electronic Data Capture (EDC).

QUINTILES ANNOUNCES RECEIPT OF REQUISITE CONSENTS DUE 2013 AND 11.5% SENIOR DISCOUNT NOTES DUE 2014

Fri, 17 Mar 2006 10:27:32 -0400

March 17, 2006 – Quintiles Transnational Corp. ("Quintiles") and Pharma Services Intermediate Holding Corp. ("Holding;" each of Holding and Quintiles, is referred to as a "Company") today announced that, in connection with the previously announced tender offer and consent solicitation for any and all of Quintiles' outstanding $450.0 million aggregate principal amount 10% senior subordinated notes due 2013 (CUSIP Nos. 748767 AE0 and 748767 AD2)(the "Subordinated Notes") and any and all of Holding's outstanding $219.0 million aggregate principal amount at maturity 11.5% senior discount notes due 2014 (CUSIP No. 71711W AB6)(the "Discount Notes"), the requisite consents have been received to approve certain amendments to the indentures under which the respective Notes were issued. The amendments to the indentures will eliminate or make less restrictive most of the restrictive covenants contained in the indentures and amend certain related provisions.

QUINTILES COMMENCES REFINANCING PROCESS

Mon, 06 Mar 2006 10:31:27 -0400

March 6, 2006 – Quintiles Transnational Corp. today announced that it is pursuing plans to borrow $1.47 billion under new credit facility arrangements. The new credit facilities would include a $250 million first lien revolving credit facility due in 2012, a $900 million first lien term loan B due in 2013 and a $320 million second lien term loan C due in 2014. Proceeds from these borrowings would be used, together with available cash, to pay the purchase price for notes tendered in the tender offer announced by the Company and Pharma Services Intermediate Holding Corp. ("Holding") on March 3, 2006, with respect to any and all of their outstanding senior notes, and to cash out the outstanding preferred stock of Pharma Services Holding, Inc., the parent company of the Company and Holding. The refinancing and the tender offer are subject to certain conditions, rights of withdrawal and other terms which could result in the Company not completing the refinancing or tender offer.

QUINTILES COMMENCES TENDER OFFER

Fri, 03 Mar 2006 10:38:57 -0400

March 3, 2006 – Quintiles Transnational Corp. today announced that it and Pharma Services Intermediate Holding Corp. ("Holding;" each of Holding and Quintiles, is referred to as a "Company") have commenced a cash tender offer for any and all of Quintiles' outstanding $450.0 million aggregate principal amount 10% senior subordinated notes due 2013 (CUSIP Nos. 748767 AE0 and 748767 AD2) (the "Subordinated Notes") and any and all of Holding's outstanding $219.0 million aggregate principal amount at maturity 11.5% senior discount notes due 2014 (CUSIP No. 71711W AB6) (the "Discount Notes"). The Subordinated Notes and the Discount Notes are collectively referred to as the "Notes." In connection with the cash tender offer, each Company is also soliciting consents to amend the indentures under which the respective Notes were issued to eliminate or make less restrictive most of the restrictive covenants contained in the indentures and amend certain related provisions.

QUINTILES TO BUILD NEW HOME FOR ALL KANSAS CITY AREA OPERATIONS

Fri, 10 Feb 2006 10:48:37 -0400

February 10, 2006 – Quintiles Transnational Corp. today announced it will build a new structure in Overland Park, Kan., to house the Clinical Development Services (CDS) and Clinical Pharmacology units now in Kansas City and the Phase I Clinical Research unit located in Lenexa, Kan.

QUINTILES LABORATORY IN BEIJING RECEIVES TWO KEY CERTIFICATIONS

Fri, 20 Jan 2006 11:00:46 -0400

January 20, 2006 – Quintiles Transnational Corp. today announced that its central laboratory operation in China has earned two significant certifications – one from the College of American Pathologists (CAP) and the other from the National Glycohemoglobin Standardization Program (NGSP).

QUINTILES REPORTS 3rd QUARTER NET REVENUE OF $470.3 MILLION, UP 19%

Mon, 14 Nov 2005 11:16:20 -0400

November 14, 2005 – Quintiles Transnational Corp. today announced financial results for the quarter ended September 30, 2005. Net revenue for third quarter 2005 was $470.3 million, an increase of 19% from net revenue of $396.5 million for third quarter 2004. Profit contribution from Quintiles' Product Development and Commercial Services groups totaled $210.5 million in third quarter 2005, up from $193.1 million for third quarter 2004.

QUINTILES TRANSNATIONAL ANNOUNCES LIVE WEBCAST FOR THIRD QUARTER EARNINGS

Thu, 10 Nov 2005 11:23:04 -0400

November 10, 2005 – Quintiles Transnational Corp. today announced that it will conduct a live webcast of its third quarter 2005 earnings release conference call on Tuesday, Nov. 15, at 11:00 a.m. EST.

QUINTILES COMPLETES AGREEMENT WITH APTUIT

Fri, 30 Sep 2005 11:28:23 -0400

Sept. 30, 2005 – Quintiles Transnational Corp. today announced the completion of the previously announced agreement with Aptuit, Inc., to enter a strategic partnership.

QUINTILES SUBSIDIARY TO PRIVATELY OFFER DULOXETINE SECURED NOTES

Fri, 19 Aug 2005 11:31:45 -0400

August 19, 2005 – Quintiles Transnational Corp. today announced that its newly formed subsidiary, Duloxetine Royalty Sub (“Royalty Sub”), intends to issue $150 million of Duloxetine Secured Notes, plus as much as $50 million to $150 million of additional notes, depending on market and other conditions. Quintiles expects to use the net proceeds it will receive from Royalty Sub to repay in full all outstanding term loans, if any, under Quintiles’ existing senior secured credit facility, for any other purposes permitted under Quintiles’ other debt arrangements and for general corporate purposes.

QUINTILES REPORTS 2nd QUARTER NET REVENUE OF $537 MILLION, UP 26 PERCENT

Fri, 12 Aug 2005 11:35:28 -0400

August 12, 2005 – Quintiles Transnational Corp. today announced financial results for the quarter ended June 30, 2005. Net revenue for second quarter 2005 was $537.4 million, an increase of 26% from net revenue of $425.8 million for second quarter 2004. Contribution from Quintiles' Product Development and Commercial Services groups totaled $243.0 million in second quarter 2005, up 28% from $189.7 million for second quarter 2004.

QUINTILES TRANSNATIONAL ANNOUNCES LIVE WEBCAST FOR SECOND QUARTER EARNINGS

Tue, 09 Aug 2005 11:40:18 -0400

August 9, 2005 – Quintiles Transnational Corp. today announced that it will conduct a live webcast of its second quarter 2005 earnings release conference call on Friday, Aug. 12, at 1:00 p.m. EDT.

FDA LEADER JOINS QUINTILES' REGULATORY GROUP

Tue, 02 Aug 2005 12:58:15 -0400

August 2, 2005 – Quintiles Transnational Corp. today announced the appointment of an expert in the regulation of pharmaceutical and biotechnology products, Edward Tabor, M.D., as Executive Director, Regulatory & Technical Services.

KIYOTAKA FUJII APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER OF QUINTILES JAPAN

Thu, 21 Jul 2005 11:47:02 -0400

July 21, 2005 – Quintiles Transnational Corp. today announced the appointment of Kiyotaka Fujii as President and Chief Executive Officer of Quintiles Transnational Japan K.K. (Quintiles Japan) as of August 1, 2005.

QUINTILES, APTUIT TO FORM STRATEGIC ALLIANCE FOR EARLY DRUG DEVELOPMENT

Tue, 19 Jul 2005 11:55:02 -0400

July 19, 2005 – Quintiles Transnational Corp., the world's leading pharmaceutical services organization, announced today that it has signed an agreement with Aptuit Inc., an emerging company focused on streamlining and supporting the early drug development process, to enter a strategic partnership. Aptuit will acquire three Quintiles business units – Preclinical Services, Pharmaceutical Sciences and Clinical Trial Supplies – for approximately $125 million, and the two companies will sign a two-year commercial agreement.

INTERPHARMA, QUINTILES AND TEMASEK TO FORM JOINT VENTURE

Thu, 09 Jun 2005 11:57:42 -0400

June 9, 2005 – Three global companies have announced a joint venture to commercialize pharmaceutical products in the Asia Pacific region. Partners in the joint venture, which will have an investment fund totaling US$112 million, include leading Asia Pacific pharmaceutical services group, Interpharma Asia Pacific, parent of drug distributor Zuellig Pharma; Asia investment company Temasek Holdings (Private) Limited; and Quintiles Transnational Corp., the world's leading pharmaceutical services organization, who has signed a letter of intent to join the venture. Each partner is expected to make an equal investment in the joint venture and own one-third each of the company.

QUINTILES LABORATORIES ASIA ENHANCES SERVICES IN CHINA

Thu, 02 Jun 2005 12:10:14 -0400

June 2, 2005 – Quintiles Transnational Corp. today announced that Quintiles Laboratories Asia (QLAB Asia) has amended its existing agreement with Peking Union Medical College Hospital (PUMCH) to enhance central laboratory services in China.

QUINTILES, MIAMI CHILDRENS HOSPITAL CREATE ALLIANCE FOR PEDIATRIC STUDIES

Tue, 31 May 2005 13:02:46 -0400

May 31, 2005 – Quintiles Inc., the North American clinical development subsidiary of Quintiles Transnational Corp., and Miami Children's Hospital in Florida today announced an alliance for clinical research.

QUINTILES REPORTS 1st QUARTER NET REVENUE OF $492 MILLION, UP 16 PERCENT

Fri, 13 May 2005 12:14:54 -0400

May 13, 2005 – Quintiles Transnational Corp. today announced financial results for the quarter ended March 31, 2005. Net revenue for first quarter 2005 was $492.4 million, an increase of 16% from net revenue of $423.2 million for the same quarter in 2004. Contribution for Quintiles' Product Development and Commercial Services groups totaled $217.2 million in first quarter 2005 versus $182.6 million for the same quarter in 2004. Net income for first quarter 2005 was $19.3 million, compared with a loss of $15.7 million for first quarter 2004.

QUINTILES DESIGNATED STRATEGIC PARTNER BY ROCHE

Thu, 12 May 2005 13:08:31 -0400

May 12, 2005 – Quintiles Transnational Corp. today announced it has entered a partnership with Roche for clinical study management services

QUINTILES TRANSNATIONAL ANNOUNCES LIVE WEBCAST FOR FIRST QUARTER EARNINGS

Wed, 11 May 2005 12:21:18 -0400

May 11, 2005 – Quintiles Transnational Corp. today announced that it will conduct a live webcast of its first quarter 2005 earnings release conference call on Monday, May 16, at 11:00 a.m. EDT.

QUINTILES REPORTS 2004 NET REVENUE OF $1.78 BILLION

Mon, 07 Mar 2005 12:27:17 -0400

March 7, 2005 – Quintiles Transnational Corp. today announced financial results for the year and quarter ended Dec. 31, 2004. Net revenue for 2004 was $1.78 billion versus $1.63 billion in 2003. Contribution for Quintiles' Product Development and Commercial Services groups totaled $808.1 million for 2004 versus $713.7 million for 2003. Net income for 2004 was $1.0 million, compared with $29.7 million for 2003.

QUINTILES TRANSNATIONAL ANNOUNCES LIVE WEBCAST OF FOURTH QUARTER EARNINGS RELEASE CONFERENCE CALL

Thu, 03 Mar 2005 12:42:17 -0400

March 3, 2005 – Quintiles Transnational Corp. today announced that it will conduct a live webcast of its fourth quarter 2004 earnings release conference call on Wednesday, March 9, at 11:00 a.m. EST.

QUINTILES ADDS SIX THERAPEUTIC EXPERTS TO STAFF

Tue, 22 Feb 2005 13:14:16 -0400

February 22, 2005 – Quintiles Transnational Corp. today announced that its Medical and Scientific Services organization has hired six more physicians for their medical expertise.

QUINTILES, UNC-CHAPEL HILL ENTER CLINICAL RESEARCH ALLIANCE

Fri, 18 Feb 2005 12:44:04 -0400

February 18, 2005 – Quintiles Inc., the North American clinical development subsidiary of Quintiles Transnational Corp., and the University of North Carolina at Chapel Hill today announced the creation of a new alliance for clinical research.

QUINTILES NAMES STEPHEN DECHERNEY PRESIDENT OF CDS AMERICAS

Mon, 22 Nov 2004 10:09:28 -0400

November 22, 2004 – Quintiles Transnational Corp. today announced the appointment of Stephen DeCherney, M.D., MPH, as President, Clinical Development Services Americas.

PACIFIC BIOMETRICS, INC. AND QUINTILES TRANSNATIONAL ANNOUNCE CENTRAL LABORATORY PARTNERSHIP

Fri, 19 Nov 2004 10:13:46 -0400

November 19, 2004 - Pacific Biometrics, Inc. (OTCBB: PBME), a provider of specialty central laboratory services, and Quintiles Transnational Corp., the world's leading provider of pharmaceutical services, today announced the signing of an agreement to co-promote and co-market central laboratory services.

QUINTILES ANNOUNCES LIVE WEBCAST FOR THIRD QUARTER EARNINGS

Fri, 12 Nov 2004 13:44:00 -0400

To access the webcast on Nov. 12, go to www.quintiles.com/Corporate_Info/Broadcast_Center. Interested parties can access the webcast or replay, which will be available through 5:00 p.m. EST Nov. 26, at www.quintiles.com/Corporate_Info/Broadcast_Center.

QUINTILES REPORTS 3Q NET REVENUE OF $440.1 MILLION, UP 9% FROM 2003

Fri, 12 Nov 2004 13:29:37 -0400

November 12, 2004 – Quintiles Transnational Corp. today announced financial results for the quarter ended Sept. 30, 2004. Net revenue for third quarter 2004 was $440.1 million, an increase of 9% from net revenue of $403.5 million for the same period in 2003. Net income for third quarter 2004 was $34.5 million versus a loss of $16.8 million for third quarter 2003.

QUINTILES NAMES DR. OREN COHEN CHIEF MEDICAL OFFICER

Mon, 27 Sep 2004 13:47:20 -0400

September 27, 2004 – Quintiles Transnational Corp. today announced the appointment of Oren Cohen, M.D., as Chief Medical and Scientific Officer, effective immediately.

J. KNIPPER & COMPANY AND INNOVEX TO PROVIDE ONLINE DRUG SAMPLING CAPABILITY

Thu, 02 Sep 2004 13:55:40 -0400

September 2, 2004 – J. Knipper & Company, Inc., an innovative marketing services company, and Innovex, a leading commercial services provider, have announced an agreement to provide an online sampling system to the pharmaceutical industry, via the iQLearning.com physician portal.

QUINTILES RECEIVES 2004 LILLY GLOBAL SUPPLIER AWARD

Wed, 01 Sep 2004 10:27:04 -0400

September 1, 2004 – Quintiles Transnational Corp. today announced that its pharmaceutical sciences division in Kansas City, Mo., has received a 2004 Lilly Global Supplier Award from Eli Lilly and Company. Quintiles is one of 11 Lilly suppliers to be honored this year.

QUINTILES REPORTS 2nd QUARTER NET REVENUE OF $426 MILLION

Fri, 13 Aug 2004 14:04:45 -0400

August 13, 2004 – Quintiles Transnational Corp. today announced financial results for the quarter ended June 30, 2004 . Net revenue for second quarter 2004 was $425.8 million versus $408.4 million for the same period in 2003. Net loss for second quarter 2004 was $10.1 million, reflecting increased costs and expenses from project startups.

QUINTILES APPOINTS CARDIAC SAFETY MEDICAL DIRECTOR

Tue, 29 Jun 2004 14:18:07 -0400

June 29, 2004 – Quintiles Transnational Corp. today announced the appointment of Dhiraj D. Narula, M.D., to the position of Medical Director, Integrated Cardiac Safety Services.

MITSUI & CO. INTENDS TO BECOME 20% SHAREHOLDER

Tue, 22 Jun 2004 14:34:32 -0400

June 22, 2004 – Quintiles Transnational Corp. and Mitsui & Co., Ltd., today announced that they expect Mitsui to become a 20% shareholder in Quintiles Transnational Japan K.K. (Quintiles Japan) in a transaction designed to accelerate Quintiles Japan's growth and expand Quintiles and Mitsui's strategic alliance capabilities in pharmaceuticals, biotechnology and healthcare.

JOHN RATLIFF APPOINTED CHIEF FINANCIAL OFFICER OF QUINTILES TRANSNATIONAL CORP.

Mon, 21 Jun 2004 14:41:40 -0400

June 21, 2004 – Quintiles Transnational Corp. today announced that John Ratliff has been appointed Chief Financial Officer, succeeding James L. Bierman, whose retirement, effective June 30, 2004, was announced earlier this year.

QUINTILES DESIGNATED CDISC REGISTERED SOLUTIONS PROVIDER

Mon, 07 Jun 2004 14:45:47 -0400

JUNE 7, 2004 – Quintiles Transnational Corp. today announced that it has been certified as a CDISC Registered Solutions Provider for managing data submitted for the approval of new medicines.

AGREEMENT EXPANDS QUINTILES CAPABILITIES TO SUPPORT DRUG APPROVALS IN JAPAN

Wed, 05 May 2004 10:36:29 -0400

May 5, 2004 –Quintiles Transnational Corp. today announced an agreement to conduct clinical trials in Peru involving ethnic Japanese, further expanding the company's ability to support new drug applications in Japan.

QUINTILES' INTEGRATED CARDIAC SAFETY GROUP APPOINTS PANEL OF EXPERT CONSULTANTS

Wed, 21 Apr 2004 14:51:48 -0400

April 21, 2004 – Quintiles Transnational Corp. today announced the appointment of three of the world's leading cardiac experts to form an advisory panel for Quintiles' Integrated Cardiac Safety Services.

QUINTILES ANNOUNCES BOARD OF DIRECTORS

Mon, 01 Mar 2004 14:57:13 -0400

March 1, 2004 – Quintiles Transnational Corp. today announced members of its new Board of Directors, which was formed following completion of the company's privatization transaction last year. As previously announced, on Sept. 25, 2003, Quintiles shareholders approved the company's acquisition by Pharma Services Holding, Inc., the company created for the acquisition of Quintiles by Dennis Gillings, Ph.D., Chairman, Chief Executive Officer and founder of Quintiles, and One Equity Partners LLC, the private equity arm of Bank One Corporation. Other equity investors in Pharma Services include Temasek Holdings, Texas Pacific Group, Perseus-Soros BioPharmaceutical Fund and Mitsui & Co.

QUINTILES INTEGRATES CARDIAC SAFETY FOR CONTINUUM OF SERVICE

Tue, 24 Feb 2004 17:27:16 -0400

February 24, 2004 – Quintiles Transnational Corp. today announced the creation of Integrated Cardiac Safety Services, designed to meet the increasing demand for cardiac safety data in the drug approval process.

QUINTILES LAUNCHES GLOBAL DIVISION FOR NON-REGISTRATION RESEARCH AND CONSULTING SERVICES

Mon, 17 Nov 2003 17:21:04 -0400

November 17, 2003 – Quintiles Transnational Corp. today announced the launch of Quintiles Strategic Research Services, a new global business division specializing in the design and delivery of non-registration research studies.

QUINTILES SIGNS AGREEMENT FOR CENTRAL LAB SERVICES IN CHINA

Tue, 21 Oct 2003 17:27:08 -0400

October 21, 2003 – Quintiles Transnational Corp. today announced an agreement with the Peking Union Medical College Hospital (PUMCH) in Beijing to expand Quintiles' central laboratory services in China.

QUINTILES COMPLETES MERGER WITH PHARMA SERVICES

Thu, 25 Sep 2003 10:48:05 -0400

September 25, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced that it has completed its merger with Pharma Services Acquisition Corp. ("Merger Sub"), a subsidiary of Pharma Services Holding, Inc. ("Pharma Services"), the company formed for the acquisition of Quintiles by Dennis B. Gillings, Ph.D., Chairman and founder of Quintiles, and One Equity Partners LLC, the private equity arm of Bank One Corporation. Other equity investors in Pharma Services include Temasek Holdings, Texas Pacific Group, Perseus-Soros BioPharmaceutical Fund (PSBF) and Mitsui & Co. Completion followed the Quintiles shareholder meeting today at which Quintiles shareholders approved the proposed merger.

QUINTILES SIGNS PURCHASE AGREEMENT TO ISSUE SENIOR SUBORDINATED NOTES

Sat, 13 Sep 2003 10:52:00 -0400

September 13, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced that it has entered into a purchase agreement through which Quintiles intends to issue and sell $450 million principal amount of 10.0% senior subordinated notes due 2013 in connection with its proposed merger with an affiliate of Pharma Services Holding, Inc., the company formed for the acquisition of Quintiles by Dennis B. Gillings, Ph.D., Chairman and founder of Quintiles, and One Equity Partners, LLC, the private equity arm of Bank One Corporation. Holders of the notes will be granted certain exchange and registration rights with respect to the notes. The proposed merger and the completion of the financing, including consummation of the transactions contemplated by the purchase agreement, are subject to customary conditions, including Quintiles' shareholder approvals.

QUINTILES SCHEDULES SPECIAL SHAREHOLDER MEETING SEPT. 25

Wed, 27 Aug 2003 10:57:17 -0400

August 27, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced that a special meeting of shareholders will be held Thursday, Sept. 25, to vote on the proposed merger agreement between Quintiles Transnational and Pharma Services Holding, Inc.

QUINTILES ANNOUNCES ITS INTENTION TO OFFER $450 MILLION OF SENIOR SUBORDINATED NOTES

Tue, 26 Aug 2003 11:16:08 -0400

August 26, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced that it intends to offer $450 million principal amount of Senior Subordinated Notes due 2013 in connection with its merger with a wholly-owned subsidiary of Pharma Services Holding, Inc., the company formed for the acquisition of Quintiles by Dennis B. Gillings, Ph.D., Chairman and founder of Quintiles, and One Equity Partners, LLC, the private equity arm of Bank One Corporation. The Notes will be guaranteed by Quintiles' U.S. subsidiaries. Holders of the Notes will be granted certain exchange and registration rights with respect to the Notes. The net proceeds will be used to finance the merger and to refinance a portion of Quintiles' existing debt. The consummation of the offering is conditioned upon the consummation of the merger.

Quintiles Transnational Reports 2nd Quarter EPS of $0.25

Tue, 12 Aug 2003 11:23:06 -0400

August 12, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced financial results for the quarter ended June 30, 2003. Earnings per share for second quarter 2003 were $0.25 on a diluted basis, a 47% increase from second quarter 2002 EPS of $0.17 and exceeding analysts' consensus expectation of $0.14 as reported by First Call. Net income for second quarter 2003 was $29.6 million, a 44% increase from second quarter 2002 net income of $20.6 million. Total gross revenues and net revenues for second quarter 2003 were $520 million and $423 million, respectively, compared to $498 million and $390 million for second quarter 2002.

QUINTILES TRANSNATIONAL ANNOUNCES LIVE WEBCAST

Wed, 06 Aug 2003 11:58:47 -0400

August 6, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced that it will conduct a live webcast of its second quarter 2003 earnings release conference call on Wednesday, Aug. 13, at 11 a.m. EDT.

QUINTILES REPORTS 1ST QUARTER EARNINGS PER SHARE OF $0.21

Mon, 21 Apr 2003 16:14:42 -0400

April 21, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced financial results for the quarter ended March 31, 2003. Income from continuing operations per share on a diluted basis for first quarter 2003 was $0.21, which represents a 48% increase from first quarter 2002 income from continuing operations per share of $0.14. Income from continuing operations for first quarter 2003 was $25.2 million, a 46% increase compared to $17.3 million from a year ago. Total gross revenues and net revenues for first quarter 2003 were $512 million and $417 million, respectively, compared to $493 million and $398 million for first quarter 2002. Earnings per share for first quarter 2002 were $0.52, including $0.38 due to the cumulative effect of a change in an accounting principle.

QUINTILES TRANSNATIONAL CORP. ANNOUNCES LIVE WEBCAST OF ITS FIRST QUARTER 2003 EARNINGS RELEASE CONFERENCE CALL

Fri, 11 Apr 2003 16:17:52 -0400

April 11, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) will conduct a live webcast of its first quarter 2003 earnings release conference call on April 22, at 11 a.m. EDT.

QUINTILES TRANSNATIONAL AND PHARMA SERVICES ANNOUNCE AGREEMENT FOR $14.50 PER SHARE CASH MERGER

Thu, 10 Apr 2003 16:28:56 -0400

April 10, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) and Pharma Services Holding, Inc. today announced that they have signed a merger agreement for Quintiles' public shareholders to receive $14.50 per share in cash. Pharma Services was founded by Dennis B. Gillings, Ph.D., Chairman of the Board and founder of Quintiles, and One Equity Partners, LLC, the private equity arm of Bank One Corporation. Dr. Gillings and certain of his affiliates will retain their equity interest in Quintiles. In addition, in order to finance the transaction, Pharma Services has received an equity commitment of $415.7 million from One Equity Partners, LLC and debt commitments totaling $875 million from Citicorp North America, Inc. and Citigroup Global Markets Inc. Pharma Services also intends to use existing Quintiles cash of approximately $586 million to fund the transaction. Citigroup is also the exclusive financial advisor to Pharma Services. The transaction, which is anticipated to be completed later this year, is subject to Pharma Services' completion of its committed financing and customary conditions, including regulatory and Quintiles' shareholder approvals.

QUINTILES PHARMACOVIGILANCE, MEDICAL AND SCIENTIFIC SERVICES CONTINUE TO ADD EXPERTISE

Wed, 19 Mar 2003 14:35:39 -0400

March 19, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced appointments within the company's Pharmacovigilance and Medical & Scientific Service Departments. Dennis Fowler, M.D., Ph.D., has joined the Pharmacovigilance Department as Senior Medical Director. Penny Randall, M.D., MBA, has joined the psychiatry team of the Medical & Scientific Services Department.

QUINTILES CELEBRATES EIGHT YEARS OF GROWTH IN SCOTLAND

Mon, 03 Mar 2003 14:50:34 -0400

March 3, 2003 – Quintiles Limited, a unit of Quintiles Transnational Corp. (Nasdaq: QTRN), today announced the eighth anniversary of its Scottish operations. Quintiles established its presence in Scotland on March 3, 1995, when it acquired the former Syntex facility in Riccarton in which it employed 194 people. Quintiles and its affiliates, Minerva Medical Ltd and the Royce Consultancy, now employ more than 1,400 employees in seven sites in Scotland.

QUINTILES ANNOUNCES EXECUTIVE APPOINTMENT IN MEDICAL & SCIENTIFIC SERVICES

Wed, 19 Feb 2003 14:58:03 -0400

February 19, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) announced today the appointment of Richard Levine, M.D., as Director, Medical & Scientific Services, for the hematology, oncology, cardiovascular and respiratory team.

QUINTILES REPORTS 4th QUARTER EARNINGS PER SHARE OF $0.19

Tue, 04 Feb 2003 16:36:13 -0400

February 4, 2003 – Quintiles Transnational Corp. (Nasdaq: QTRN) today announced financial results for the quarter and year ended Dec. 31, 2002. Earnings per share on a diluted basis for fourth quarter 2002 were $0.19, which exceeded analysts' estimates of $0.18, and net income for the quarter was $22.6 million. Earnings per share on a diluted basis and net income for fourth quarter 2001 were $0.60 and $72.6 million respectively, including certain non-recurring events. In fourth quarter 2001, Quintiles recognized a non-recurring pre-tax net gain of $84.7 million that included a gain on the sale of WebMD common stock less a write-off of goodwill and other assets. This gain is included in the $0.60 earnings per share reported in fourth quarter 2001.

NEW FDA HEAD SAYS CLINICAL RESEARCH ORGANIZATIONS ARE VITAL TO ENHANCING DRUG DEVELOPMENT PROCESS

Thu, 21 Nov 2002 15:46:26 -0400

November 21, 2002 – The new commissioner of the U.S. Food and Drug Administration (FDA) says clinical research organizations (CROs) will play an important role in working with the FDA in continuing to enhance the development of new and effective medicines in the United States. Mark B. McClellan, M.D., Ph.D., spoke this week to the heads of 30 leading CROs at an event hosted by the Association of Clinical Research Organizations (ACRO).

QUINTILES TRANSNATIONAL SPECIAL COMMITTEE REJECTS PROPOSAL BY PHARMA SERVICES COMPANY TO ACQUIRE ALL OUTSTANDING SHARES

Mon, 11 Nov 2002 14:18:27 -0400

November 11, 2002 - The Special Committee of the Quintiles Transnational Corp. (Nasdaq: QTRN) Board of Directors announced today that it had rejected the proposal by Pharma Services Company to acquire all outstanding shares of Quintiles common stock for $11.25 per share as inadequate and not in the best interests of Quintiles and its shareholders. The conclusion of the Special Committee was reached after careful consideration, including a thorough review with its independent financial advisor, Morgan Stanley, and its independent legal advisor, Willkie Farr & Gallagher. Pharma Services Company is wholly owned by Dennis B. Gillings, Ph.D., Chairman of the Board and Founder of Quintiles. Its non-binding proposal was announced on October 14.

QUINTILES ACQUIRES MAJORITY STAKE IN LATE-PHASE CLINICAL RESEARCH CONSULTING AND STUDY DESIGN COMPANY

Tue, 29 Oct 2002 15:06:19 -0400

October 29, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the acquisition of a controlling interest in Health Research Solutions Pty Ltd, an Australian company specializing in multi-national late-phase clinical research.

QUINTILES TRANSNATIONAL CORP. UPDATES SPECIAL COMMITTEE ACTIVITIES

Fri, 25 Oct 2002 14:04:11 -0400

October 25, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced that the recently constituted special committee of its Board of Directors has engaged Morgan Stanley to act as its financial advisor. Members of the special committee are Robert C. Bishop, Ph.D., Vaughn D. Bryson and Virginia V. Weldon, M.D. The special committee also has engaged Willkie Farr & Gallagher as its legal counsel.

QUINTILES REPORTS 3rd QUARTER EPS OF $0.18; ACHIEVES RECORD CASH FLOW FROM OPERATIONS OF $77 MILLION

Wed, 16 Oct 2002 11:40:32 -0400

October 16, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced financial results for third quarter 2002. Earnings per share for the quarter ended Sept. 30, 2002, were $0.18 on a diluted basis, exceeding analysts' consensus expectations and up from a third quarter 2001 loss of $1.03 per share. On an operating basis, third quarter 2001 EPS was $0.04, excluding non-recurring events. Net revenue and net income for third quarter 2002 were $396.9 million and $21.2 million, respectively, compared to third quarter 2001 net revenue of $399.4 million and a net loss of $123.9 million. Operating basis net income for third quarter 2001, excluding non-recurring events, was $5.1 million. Non-recurring events in 2001 included restructuring charges, write-off of goodwill and other assets, impairment on the investment in WebMD common stock, and gain on disposal of a discontinued operation. Please refer to the attached financial tables for further details.

QUINTILES TRANSNATIONAL RECEIVES PROPOSAL FROM DENNIS GILLINGS TO ACQUIRE QUINTILES

Mon, 14 Oct 2002 11:26:16 -0400

October 14, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced that Pharma Services Company, a newly formed company wholly owned by Dennis B. Gillings, Ph.D., Chairman of the Board and Founder of Quintiles, has made a non-binding proposal to acquire all of the outstanding shares of Quintiles for a cash price of $11.25 per share. Quintiles' Common Stock closed at $8.31 on October 11, 2002.

QUINTILES TRANSNATIONAL CORP. ANNOUNCES LIVE WEBCAST OF ITS THIRD QUARTER 2002 EARNINGS RELEASE CONFERENCE CALL

Wed, 09 Oct 2002 11:00:52 -0400

To access the webcast, go to www.quintiles.com/corporate_info/broadcast_center (access expired). A replay of the webcast will be available via the same link about two hours after completion of the call, and will be archived for on-demand replay through 5 p.m. EST on Friday, November 1, 2002.

QUINTILES NAMES RAY DAWKINS DIRECTOR, MEDICAL & SCIENTIFIC SERVICES

Wed, 02 Oct 2002 15:21:19 -0400

October 2, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced today that Ray Dawkins, M.D., has joined its North American Clinical Development Services unit as Director, Medical & Scientific Services.

QUINTILES JAPAN, SRL FORM STRATEGIC ALLIANCE FOR CLINICAL DEVELOPMENT SERVICES IN JAPAN

Tue, 27 Aug 2002 16:04:09 -0400

August 27, 2002 - Quintiles Transnational Japan K.K. and SRL, Inc., today announced the creation of a strategic alliance to provide clinical trial laboratory and other services to pharmaceutical and biotechnology customers in Japan.

QUINTILES ANNOUNCES ENHANCED CENTRALIZED ECG MONITORING SERVICES THROUGH NEW QECG UNIT

Thu, 01 Aug 2002 16:11:54 -0400

August 1, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the launch of QECG, an enhanced centralized electrocardiogram (ECG) service to help pharmaceutical and biotechnology companies analyze ECG data from clinical trials and use digital ECG data in submissions to regulatory authorities.

QUINTILES' 2nd QUARTER EPS OF $0.17 EXCEEDS CONSENSUS EXPECTATIONS; STRONG CASH FLOW FROM OPERATIONS OF $49 MILLION

Wed, 17 Jul 2002 14:09:53 -0400

July 17, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced financial results for second quarter 2002. Earnings per share for the quarter ended June 30, 2002, were $0.17 on a diluted basis, exceeding analysts' consensus expectations and up from second quarter 2001 earnings per share of $0.09, excluding the $2.1 million restructuring charge incurred in 2001. Net revenue and net income for second quarter 2002 were $390.3 million and $20.6 million, respectively, compared to $406.6 million and $11.1 million, excluding the 2001 restructuring charge, for second quarter 2001.

QUINTILES TRANSNATIONAL CORP. ANNOUNCES LIVE WEBCAST OF ITS SECOND QUARTER 2002 EARNINGS RELEASE CONFERENCE CALL

Thu, 11 Jul 2002 16:23:45 -0400

July 11, 2002 - Quintiles Transnational Corp. will conduct a live webcast of its second quarter 2002 earnings release conference call on July 18, 2002, at 11:00 a.m. EDT.

QUINTILES TRANSNATIONAL CORP. ANNOUNCES LIVE WEBCAST OF ITS SECOND QUARTER 2002 EARNINGS RELEASE CONFERENCE CALL

Thu, 11 Jul 2002 11:39:08 -0400

July 11, 2002 - Quintiles Transnational Corp. will conduct a live webcast of its second quarter 2002 earnings release conference call on July 18, 2002, at 11:00 a.m. EDT.

QUINTILES, HAWAII PACIFIC HEALTH FORM EXCLUSIVE ALLIANCE TO SERVE PHARMA COMPANIES SEEKING PRODUCT APPROVAL IN JAPAN

Thu, 06 Jun 2002 16:36:25 -0400

June 6, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) and Hawaii Pacific Health today announced an exclusive collaborative agreement to support new drug applications in Japan by conducting clinical trials in Hawaii involving the state's large population of ethnic Japanese.

VERISPAN, HEALTHCARE INFORMATICS VENTURE OF MCKESSON & QUINTILES, BEGINS OPERATION

Mon, 20 May 2002 14:55:23 -0400

May 20, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) and McKesson Corporation (NYSE: MCK) today announced that they have completed formation of a healthcare informatics joint venture, named Verispan, L.L.C., which is the nation's leading provider of patient-level, longitudinal data. The companies previously announced their intent to form the venture on March 18, 2002.

QUINTILES REPORTS 1st QUARTER 2002 EPS OF $0.14, CASH FLOW FROM OPERATIONS OF $55 MILLION

Wed, 17 Apr 2002 11:09:35 -0400

April 17, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced financial results for first quarter 2002. Earnings per share for the quarter ended March 31, 2002, were $0.14 on a diluted basis, meeting analysts' consensus expectations and a 133% increase from first quarter 2001 reported earnings per share of $0.06. Total net revenues and net income for first quarter 2002 were $398.1 million and $17.3 million, respectively, compared to $403.6 million and $7.8 million for first quarter 2001.

ORION, QUINTILES SIGN LETTER OF INTENT TO FORM DRUG DEVELOPMENT VENTURE

Mon, 15 Apr 2002 16:40:33 -0400

April 15, 2002 - Orion Corporation (Hex: ORIBS) and Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the signing of a letter of intent to form a drug development venture to develop a portfolio of selected proprietary products currently in Phases I through III from Orion Pharma, the pharmaceutical division of Orion Corporation. Orion and Quintiles will have a non-controlling minority interest in the new company, and plan to offer a majority ownership to outside investors.

MCKESSON CORPORATION, QUINTILES TRANSNATIONAL CORP. ANNOUNCE LIVE WEBCAST TO DISCUSS THE CREATION OF LEADING HEALTHCARE

Mon, 18 Mar 2002 11:56:05 -0400

March 18, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) and McKesson Corporation (NYSE: MCK) will conduct a live webcast on Tuesday, March 19, 2002 at 11 a.m. EST to discuss their formation of a joint venture to create a leading healthcare information services company. Senior management from McKesson, Quintiles and the joint venture will discuss the formation of the new company and will be available to answer questions.

BIOFOCUS AND QUINTILES ANNOUNCE LAUNCH OF NEW HIGH-THROUGHPUT SCREENING SERVICE TO DETECT CARDIO-TOXIC COMPOUNDS

Tue, 19 Feb 2002 16:47:19 -0400

19 February 2002 -- BioFocus plc (LSE: BIO) and Quintiles Transnational Corp. (Nasdaq: QTRN) have announced the launch of a new screening service for the rapid and early detection of potential cardiac side-effects caused by drug candidates and lead molecules. The two companies will jointly market the new service. The assay work will be carried out at BioFocus' advanced biology facility at Cambridge Science Park in the United Kingdom.

QUINTILES CONSULTING LAUNCHES NEW SERVICE TO HELP MANUFACTURERS PREPARE FOR FDA PRE-APPROVAL INSPECTION

Mon, 11 Feb 2002 16:54:54 -0400

February 11, 2002 - Quintiles Consulting today announced the launch of MARKETREADY™, a comprehensive, step-by-step process to help manufacturers of medicines and medical devices meet regulatory standards in pre-approval inspections.

QUINTILES REPORTS 4TH QUARTER EPS OF $0.14 BEFORE ONE-TIME GAINS, UP 56% FROM PREVIOUS QUARTER

Wed, 23 Jan 2002 11:50:51 -0400

January 23, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced financial results for the quarter and year ended Dec. 31, 2001. Earnings per share for fourth quarter 2001 were $0.14 on a diluted basis, a 56% increase from the previous quarter's reported earnings per share of $0.09, excluding non-recurring events. First Call's consensus estimate for fourth quarter 2001 earnings per share was $0.11. Income from operations, excluding non-recurring events, was $18.6 million vs. $11.7 million for the previous quarter, a 59% increase. Net income for the quarter was $17 million, a 64% increase from the previous quarter's net income of $10.4 million, excluding non-recurring events. Net revenue for the quarter was $404 million, compared to $407 million for third quarter 2001. Non-recurring events included restructuring charges, write-off of goodwill and other assets, disposal of business and WebMD-related transactions. Please refer to the attached financial tables for further details.

QUINTILES TRANSNATIONAL CORP. ANNOUNCES LIVE WEBCAST OF ITS FOURTH QUARTER 2001 EARNINGS RELEASE CONFERENCE CALL

Thu, 17 Jan 2002 13:49:47 -0400

January 17, 2002 - Quintiles Transnational Corp. will conduct a live webcast of its fourth quarter 2001 earnings release conference call on Jan. 24, 2002, at 11:00 a.m. EST.

TRACY TSUETAKI JOINS QUINTILES TRANSNATIONAL AS HEAD OF GLOBAL BUSINESS DEVELOPMENT

Wed, 16 Jan 2002 15:29:55 -0400

January 16, 2002 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the following executive appointment:

QUINTILES ANNOUNCES FIVE-YEAR GLOBAL STRATEGIC ALLIANCE WITH PHARMACIA

Tue, 11 Dec 2001 16:38:32 -0400

December 11, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced that it has entered into a strategic alliance with Pharmacia Corporation of Peapack, New Jersey, to provide clinical development and laboratory services to Pharmacia worldwide. The five-year agreement expands the relationship globally that Quintiles and Pharmacia formed last year when Quintiles acquired Pharmacia's clinical development unit in Stockholm.

QUINTILES ANNOUNCES LIVE WEBCAST OF ITS INVESTOR MEETING TODAY

Tue, 11 Dec 2001 11:58:40 -0400

December 11, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) will conduct a live Webcast of its Investor Meeting today, Tuesday, Dec. 11. The event, which will take place from 9 a.m. to 12:30 p.m. (EST), will feature presentations by the companys senior management. A question-and-answer session will follow the presentations.

QUINTILES ANNOUNCES STRATEGIC ALLIANCE WITH FIRST GENETIC TRUST FOR PHARMACOGENETICS COLLABORATION

Thu, 29 Nov 2001 11:00:20 -0400

November 29, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) and First Genetic Trust, Inc., today announced the formation of a strategic alliance to develop pharmacogenetic services to advance drug development.

QUINTILES ANNOUNCES LIVE WEBCAST OF ITS DEC. 11 INVESTOR MEETING

Wed, 28 Nov 2001 12:41:43 -0400

November 28, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) will conduct a live Webcast of its Investor Meeting on Tuesday, Dec. 11. The event, which will take place from 9 a.m. to 12:30 p.m. (EST), will feature presentations by the company's senior management. A question-and-answer session will follow the presentations.

QUINTILES DESCRIBES NATIONAL EARLY WARNING SYSTEM FOR BIOTERRORISM IN TESTIMONY TODAY AT CONGRESSIONAL HEARING

Thu, 01 Nov 2001 12:51:57 -0400

November 1, 2001 - Detection of possible bioterror events could be speeded by hours or days through an electronic disease surveillance system using existing medical and pharmaceutical claims data, Quintiles Transnational Executive Vice President John Russell said today at a House subcommittee hearing on bioterrorism preparedness.

QUINTILES INFORMATICS ANNOUNCES NEW DATA CONTRACTS, PLANS TO SIGNIFICANTLY EXPAND CURRENT DATA VOLUME

Fri, 19 Oct 2001 12:56:55 -0400

October 19, 2001 - Quintiles Informatics announced today that it had signed data agreements with nine pharmacy chains and plans to significantly expand its current volume of de-identified healthcare claims data in 2002. Under a settlement agreement recently announced by Quintiles and WebMD, Quintiles will no longer receive WebMD data after February 28, 2002.

QUINTILES REPORTS INCOME FROM OPERATIONS OF $11.7 MILLION BEFORE NON-RECURRING TRANSACTIONS

Wed, 17 Oct 2001 13:02:30 -0400

Quintiles Transnational Corp. (Nasdaq: QTRN) today announced financial results for third quarter 2001. Net revenue for the quarter ended Sept. 30, 2001, was $407.1 million, compared to $404.3 million for second quarter 2001. Income from operations, excluding non-recurring transactions, was $11.7 million vs. $9.9 million for the previous quarter. Net income, excluding non-recurring transactions, was $10.4 million vs. comparable net income for the previous quarter of $11.1 million. Earnings per share on a diluted basis, excluding non-recurring transactions, were $0.09, unchanged from the previous quarter.

QUINTILES TRANSNATIONAL, CARE CAPITAL ENTER CO-INVESTMENT AGREEMENT WITH D-PHARM

Tue, 16 Oct 2001 16:45:27 -0400

October 16, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) and Care Capital LLC today announced a joint private investment of $10 million in D-Pharm, Ltd., a biopharmaceutical company based in Israel that is expanding its development capabilities in the United States.

QUINTILES ANNOUNCES PHYSICIAN APPOINTMENTS IN CLINICAL DEVELOPMENT UNIT

Mon, 15 Oct 2001 17:09:03 -0400

October 15, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) announces the following physician appointments in clinical development:

QUINTILES TRANSNATIONAL CORP. ANNOUNCES LIVE WEBCAST OF ITS THIRD QUARTER 2001 EARNINGS RELEASE CONFERENCE CALL

Mon, 15 Oct 2001 15:14:57 -0400

October 15, 2001 - Quintiles Transnational Corp. will conduct a live Webcast of its third quarter 2001 earnings release conference call on October 18, 2001, at 11:00 a.m. EDT.

QUINTILES AND WEBMD ANNOUNCE SETTLEMENT AGREEMENT

Fri, 12 Oct 2001 15:16:54 -0400

October 12, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) and WebMD Corporation (Nasdaq: HLTH) today mutually announced the settlement of the litigation between the companies and the resolution of their disputes.

QUINTILES LAUNCHES SAFETY PHARMACOLOGY UNIT IN UNITED STATES

Tue, 09 Oct 2001 17:06:02 -0400

October 9, 2001 -- Quintiles Transnational Corp. (Nasdaq:QTRN) today announced the opening of its safety pharmacology unit in Kansas City, Missouri. A new guideline on safety pharmacology issued by the International Conference on Harmonization (ICH) has prompted a growing demand for the company's safety pharmacology services worldwide.

QUINTILES TO FILE AMENDED COMPLAINT; BELIEVES APPEAL BY WEBMD IS FINANCIALLY MOTIVATED

Tue, 09 Oct 2001 15:22:34 -0400

October 9, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) intends to file an amended complaint today in U.S. District Court for the Eastern District of North Carolina seeking continued enforcement of its Data Rights Agreement with WebMD (Nasdaq: HLTH) and asserting further claims in its litigation with WebMD that began in February 2001.

QUINTILES ESTABLISHES DEDICATED RESOURCES TO MEET GLOBAL DEMAND FOR LATE PHASE STUDY SERVICES

Wed, 03 Oct 2001 10:34:07 -0400

October 3, 2001 - To enhance the depth of services it provides in support of late phase product development, Quintiles Transnational Corp. (Nasdaq: QTRN) announced the formation of Quintiles Late Phase, an international effort dedicated to helping pharmaceutical and biotech companies bridge clinical development and product commercialization.

QUINTILES, MEDICAL CORPORATION LTA OF JAPAN ANNOUNCE PHASE I SCIENTIFIC ALLIANCE

Thu, 13 Sep 2001 10:42:10 -0400

September 13, 2001 - To help pharmaceutical companies more efficiently conduct "two sites, one protocol" Phase I trials in Japan and at other sites in the United States and Europe, Quintiles Transnational Corp. (Nasdaq: QTRN) and Medical Corporation LTA today announced a scientific alliance.

QUINTILES ANNOUNCES OPERATIONAL PLAN, TARGETS FOR 2002 EARNINGS

Tue, 11 Sep 2001 17:24:03 -0400

September 11, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced its new operational plan, which is the result of a five-month review led by Chief Executive Officer Pam Kirby, Ph.D. Highlights of the plan include:

QUINTILES TRANSNATIONAL CORP. ANNOUNCES LIVE WEBCAST OF ITS SEPTEMBER 11 INVESTOR BRIEFING

Tue, 04 Sep 2001 16:04:27 -0400

September 4, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) will conduct a live Webcast of its Investor Briefing on September 11. The event, which will take place from 9:00 a.m. to 11:00 a.m. (EDT) in New York City, will feature presentations by Chief Executive Officer Pam Kirby, Ph.D., and Chief Financial Officer Jim Bierman. A question and answer session will follow the presentations.

QUINTILES' PHARMABIO DEVELOPMENT, NOVIA PHARMACEUTICALS ANNOUNCE STRATEGIC ALLIANCE FOR CENTRAL NERVOUS SYSTEM COMPOUND

Wed, 22 Aug 2001 16:54:51 -0400

August 22, 2001 - Quintiles Transnational Corp. (Nasdaq: QTRN) and Novia Pharmaceuticals Ltd. today announced a strategic alliance to provide preclinical services for Novia's lead compound to treat central nervous system (CNS) disorders.